High performance plasma amyloid-β biomarkers for Alzheimer's disease
A Nakamura, N Kaneko, VL Villemagne, T Kato… - Nature, 2018 - nature.com
To facilitate clinical trials of disease-modifying therapies for Alzheimer's disease, which are
expected to be most efficacious at the earliest and mildest stages of the disease,, supportive …
expected to be most efficacious at the earliest and mildest stages of the disease,, supportive …
[引用][C] High performance plasma amyloid-β biomarkers for Alzheimer's disease
A Nakamura, N Kaneko, VL Villemagne, T Kato… - Nature, 2018 - ideas.repec.org
High performance plasma amyloid-β biomarkers for Alzheimer’s disease IDEAS home Advanced
search Economic literature: papers, articles, software, chapters, books. Authors Institutions …
search Economic literature: papers, articles, software, chapters, books. Authors Institutions …
[引用][C] High performance plasma amyloid-β biomarkers for Alzheimer's disease
A Nakamura, N Kaneko, VL Villemagne, T Kato… - Nature, 2018 - cir.nii.ac.jp
High performance plasma amyloid-β biomarkers for Alzheimer’s disease | CiNii Research CiNii
国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
High performance plasma amyloid-β biomarkers for Alzheimer's disease
A Nakamura, N Kaneko, VL Villemagne, T Kato… - …, 2018 - ui.adsabs.harvard.edu
To facilitate clinical trials of disease-modifying therapies for Alzheimer's disease, which are
expected to be most efficacious at the earliest and mildest stages of the disease, supportive …
expected to be most efficacious at the earliest and mildest stages of the disease, supportive …
[引用][C] High performance plasma amyloid-β biomarkers for Alzheimer's disease
A Nakamura, N Kaneko, VL Villemagne, T Kato… - Nature, 2018 - econpapers.repec.org
EconPapers: High performance plasma amyloid-β biomarkers for Alzheimer’s disease
EconPapers Economics at your fingertips EconPapers Home About EconPapers Working …
EconPapers Economics at your fingertips EconPapers Home About EconPapers Working …
High performance plasma amyloid-β biomarkers for Alzheimer's disease
A Nakamura, N Kaneko, VL Villemagne, T Kato… - 2018 - ro.ecu.edu.au
To facilitate clinical trials of disease-modifying therapies for Alzheimer's disease, which are
expected to be most efficacious at the earliest and mildest stages of the disease 1, 2 …
expected to be most efficacious at the earliest and mildest stages of the disease 1, 2 …
High performance plasma amyloid-β biomarkers for Alzheimer's disease.
A Nakamura, N Kaneko, VL Villemagne, T Kato… - Nature, 2018 - europepmc.org
To facilitate clinical trials of disease-modifying therapies for Alzheimer's disease, which are
expected to be most efficacious at the earliest and mildest stages of the disease, supportive …
expected to be most efficacious at the earliest and mildest stages of the disease, supportive …
High performance plasma amyloid-β biomarkers for Alzheimer's disease
A Nakamura, N Kaneko, VL Villemagne, T Kato… - …, 2018 - pubmed.ncbi.nlm.nih.gov
To facilitate clinical trials of disease-modifying therapies for Alzheimer's disease, which are
expected to be most efficacious at the earliest and mildest stages of the disease, supportive …
expected to be most efficacious at the earliest and mildest stages of the disease, supportive …
High performance plasma amyloid-β biomarkers for Alzheimer's disease.
A Nakamura, N Kaneko, VL Villemagne, T Kato… - 2018 - ahro.austin.org.au
To facilitate clinical trials of disease-modifying therapies for Alzheimer's disease, which are
expected to be most efficacious at the earliest and mildest stages of the disease, supportive …
expected to be most efficacious at the earliest and mildest stages of the disease, supportive …
High performance plasma amyloid-biomarkers for Alzheimers disease
A Nakamura, N Kaneko, VL Villemagne, T Kato… - Nature, 2018 - go.gale.com
To facilitate clinical trials of disease-modifying therapies for Alzheimers disease, which are
expected to be most efficacious at the earliest and mildest stages of the disease [1, 2] …
expected to be most efficacious at the earliest and mildest stages of the disease [1, 2] …